Company: CDLX
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001666071-25-000126
Chunk: 104

Company: Cardlytics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 104
---
Total Common Stock SharesAmountBalance – March 31, 202448,174 $9 $1,331,628 $3,047 $(1,135,547)$199,137 Stock-based compensation— — 13,843 — — 13,843 Settlement of restricted stock986 — — — — — Issuance of common stock, net of issuance costs - ATM Offering Program (as defined below)— — (171)— — (171)Issuance of common stock pursuant to the 2018 ESPP (as defined below)242 — 1,461 — — 1,461 Termination of capped calls related to 2020 Convertible Senior Notes— — 115 — — 115 Other comprehensive loss— — — (94)— (94)Net Loss— — — — (4,257)(4,257)Balance – June 30, 202449,402 $9 $1,346,876 $2,953 $(1,139,804)$210,034 

See notes to the condensed consolidated financial statements7

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Amounts in thousands)

 Six Months EndedJune 30, 20252024Operating activitiesNet Loss$(22,565)$(28,532)Adjustments to reconcile net loss to net cash used in operating activities:Credit loss expense1,833 3,761 Depreciation and amortization12,566 12,779 Amortization of financing costs charged to interest expense804 850 Amortization of right-of-use assets1,274 1,072 Gain on disposal or divestiture(5,150)— Gain on debt extinguishment— (13,017)Stock-based compensation expense16,195 23,629 Change in contingent consideration102 9 Other non-cash (income) expense, net(8,076)663 Change in operating assets and liabilities:Accounts receivable10,165 14,783 Prepaid expenses and other assets(1,625)(393)Accounts payable(1,837)810 Other accrued expenses920 (7,253)Partner Share liability(5,913)(15,114)Consumer Incent